2014 News Releases

iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS

November 4, 2014, Vancouver, Canada â€" iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO) (OTCQX: ICOTF), today announced that presentations regarding the company’s Oral Amphotericin B drug candidate will be made at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. The event takes place at the San Diego Convention Center November 2 â€" 6.

Dr. Kishor M. Wasan, Professor and Dean, College of Pharmacy and Nutrition at the University of Saskatchewan, will present the following:

  • Poster on November 4 between 9:30 and 12:30: T2099 - Novel Oral Amphotericin B Formulation Remains Highly Effective against Murine Systemic Candidiasis following Exposure to Tropical Temperature
  • Panel Moderation on November 5 from 9:00 â€" 11:00: Antimicrobials, Super BUGS and Global Health
  • Presentation on November 5 from 2:25 to 2:50: Development of a Tropically Stable Oral Lipid Formulation of Amphotericin B for the Treatment of Systemic Fungal Infections and Visceral Leishmaniasis

Dr. Kishor Wasan, along with Dr. Ellen Wasan, Assistant Professor, College of Pharmacy and Nutrition, University of Saskatchewan, invented the delivery technology at the University of British Columbia in 2008.

About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company has exclusive worldwide rights to iCo-007 and iCo-008, as well as an oral drug delivery platform. The first platform candidate being tested is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat latent HIV reservoirs, parasitic and life-threatening infectious diseases. iCo trades on the TSX Venture Exchange under the symbol "ICO" and the OTCQX under the symbol “ICOTF”. For more information, visit the Company website at: www.icotherapeutics.com.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements
Certain statements included in this press release may be considered forward-looking statements” within the meaning of applicable securities laws.  Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods and includes, but is not limited to, statements about the intended use of proceeds of the Offering. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Mr. John Meekison, CFO
iCo Therapeutics
604-602-9414 x 224
meekison@icotherapeutics.com
Michael Moore, Investor Relations
TMX Equicom
858-886-7813
mmoore@tmxequicom.com
Copyright 2015 ICO Therapeutics | Disclaimer